Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met-Reference-Cited by-同舟云学术

Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met

Published:2009-09 Issue:1-2 Volume:284 Page:158-162
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Dardiotis Efthimios,Koutsou Pantelitsa,Zamba-Papanicolaou Eleni,Vonta Ilia,Hadjivassiliou Marilena,Hadjigeorgiou Georgios,Cariolou Marios,Christodoulou Kyproula,Kyriakides Theodoros

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology

Reference38 articles.

1. Transthyretin related familial amyloid polyneuropathy;Plante-Bordeneuve;Curr Opin Neurol,2000

2. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration;Hou;Febs J,2007

3. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves;Andrade;Brain,1952

4. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden;Andersson;Acta Med Scand Suppl,1976

5. Familial amyloid polyneuropathy: new developments in genetics and treatment;Coelho;Curr Opin Neurol,1996

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability;Journal of Neurology;2024-06-22

2. Targeted sequencing of selected functional genes in patients with wild-type transthyretin amyloidosis;BMC Research Notes;2023-10-02

3. Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction;Frontiers in Neurology;2023-07-17

4. Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy;Current Neuropharmacology;2023-03

5. Dissecting pathophysiology of a human dominantly inherited disease, familial amyloidotic polyneuropathy, by using genetically engineered mice;Frigid Zone Medicine;2022-05-01